Among the inherited metabolic diseases, Gaucher disease (GD) is of particular importance since it is the most prevalent lysosomal storage disease. GD has marked clinical heterogeneity within and among the three Types: These distinct Types result from the deficient activity (5-20%) of acid beta-glucosidase (beta-Glc). The overall objective of the proposed research is to elucidate the molecular bases of the various enzymatic defects which underlie this remarkable phenotypic heterogeneity in Gaucher disease (GD). Already the rich genetic diversity in the GD Types and variants has been indicated by the identification of seven missense mutations and additional mutant alleles in the GD population. This heterogeneity will be determined by sequencing amplified beta-Glc cDNAs from patients with unidentified alleles and/or having residual enzymes with unique biochemical properties (e.g., increased stability). Ten cDNA libraries already have been made in this laboratory. The frequency of mutations and their correlation with phenotypic severity will be determined from population studies (>300 GD patients) using amplified genomic DNA and allele specific probes. To account for the large phenotypic variation among genotypically identical (beta-Glc locus) patients, our GLBA (SAP-2) cDNA will be evaluated as a candidate modifier gene by determining the correlation of RFLPs at this locus with GD severity in selected affected siblings with differing degrees of involvement. The functional perturbations of beta-Glc caused by authentic GD mutations will be determined by systematic kinetic, processing and/or stability studies of the enzyme expressed from mutant CDNAs using our eukaryotic (Baculovirus, CHO or human) systems. Additional residues critical to beta-Glc catalytic activity or negatively-charged phospholipid (NCP) interactions will be assigned using affinity ligands (e.g., photoactivable substrate or NCPs analogues and/or binding site specific antibodies) to identify beta-Glc peptides for amino acid sequence analysis. Our demonstration that beta-Glc expressed in an unglycosylated form was inactive implicates N-glycosylation site occupancy in the modulation of catalytic activity. To elucidate this role, our beta-Glc cDNA having each of the five potential N-glycosylation sites individually destroyed (Asn->Gln) or those with various combinations of mutated sites will be expressed and the catalytic properties systematically evaluated. Similarly the localization (by cell fractionation and immunoelectronmicroscopy) of truncated beta-Glcs expressed from deletion mutants transfected into CRIMneg fibroblasts will define the mannose-6-phosphate independent signals for lysomal targeting of this membrane associated enzyme. The results of these studies should provide a basis for the design of biologicals with enhanced activities for future therapeutic interventions in GD. In addition, phenotype/genotype correlations by molecular analyses will facilitate the presymptomatic prediction of GD severity as a necessary prelude to the critical evaluation of the efficacy of genic therapeutic strategies in this prototype inborn error or metabolism.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK036729-09
Application #
3235218
Study Section
Biochemistry Study Section (BIO)
Project Start
1992-07-15
Project End
1995-12-31
Budget Start
1993-01-29
Budget End
1993-12-31
Support Year
9
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Cincinnati Children's Hospital Medical Center
Department
Type
DUNS #
071284913
City
Cincinnati
State
OH
Country
United States
Zip Code
45229
Dai, Mei; Liou, Benjamin; Swope, Brittany et al. (2016) Progression of Behavioral and CNS Deficits in a Viable Murine Model of Chronic Neuronopathic Gaucher Disease. PLoS One 11:e0162367
Burrow, Thomas A; Sun, Ying; Prada, Carlos E et al. (2015) CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings. Mol Genet Metab 114:233-241
Sun, Ying; Florer, Jane; Mayhew, Christopher N et al. (2015) Properties of neurons derived from induced pluripotent stem cells of Gaucher disease type 2 patient fibroblasts: potential role in neuropathology. PLoS One 10:e0118771
Kitatani, Kazuyuki; Wada, Masayuki; Perry, David et al. (2015) Activation of p38 Mitogen-Activated Protein Kinase in Gaucher's Disease. PLoS One 10:e0136633
Dasgupta, Nupur; Xu, You-Hai; Li, Ronghua et al. (2015) Neuronopathic Gaucher disease: dysregulated mRNAs and miRNAs in brain pathogenesis and effects of pharmacologic chaperone treatment in a mouse model. Hum Mol Genet 24:7031-48
Barnes, Sonya; Xu, You-Hai; Zhang, Wujuan et al. (2014) Ubiquitous transgene expression of the glucosylceramide-synthesizing enzyme accelerates glucosylceramide accumulation and storage cells in a Gaucher disease mouse model. PLoS One 9:e116023
Xu, You-hai; Xu, Kui; Sun, Ying et al. (2014) Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. Hum Mol Genet 23:3943-57
Liou, Benjamin; Haffey, Wendy D; Greis, Kenneth D et al. (2014) The LIMP-2/SCARB2 binding motif on acid ?-glucosidase: basic and applied implications for Gaucher disease and associated neurodegenerative diseases. J Biol Chem 289:30063-74
Pandey, Manoj Kumar; Jabre, Nicholas A; Xu, You-Hai et al. (2014) Gaucher disease: chemotactic factors and immunological cell invasion in a mouse model. Mol Genet Metab 111:163-71
Watson, Carey L; Mahe, Maxime M; MĂșnera, Jorge et al. (2014) An in vivo model of human small intestine using pluripotent stem cells. Nat Med 20:1310-4

Showing the most recent 10 out of 110 publications